Aug
18
2020

Regenerative medicine sector on pace for exceptional year

BioWorld

A first half of the year progress report from the international advocacy group Alliance for Regenerative Medicine (ARM), finds that the regenerative medicine and advanced therapy sector is in very good shape and has performed well in terms of both clinical development and fundraising despite the challenges posed by the ongoing COVID-19 pandemic.

Aug
14
2020

Record Funding for Gene and Cell Therapy Accompanies Turbulent Times

Labiotech.eu

European companies developing advanced therapies such as gene and cell therapies secured at least €2.2B ($2.6B) in the first half of 2020. While this is encouraging in the face of COVID-19, it hasn’t been smooth sailing for all startups in the field, with many struggling to stay afloat during crippling national lockdowns.

Aug
07
2020

Regenerative meds and advanced therapies sector thriving despite COVID-19

Pharma Letter

Regenerative meds and advanced therapies sector thriving …
Cutting edge therapies celebrated new milestones, including initial clinical data in gene editing, with several therapies poised for approval in the coming months.

Aug
06
2020

In the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report

Fierce Biotech

“All this enthusiasm for this sector right now is evidenced by these really astonishing financing numbers… I think the drivers of that enthusiasm remain in place and make me optimistic for the second half of 2020,” ARM CEO Janet Lambert said. “We continue to see really promising clinical results. We continue to see products making it to market. We continue to see patient, regulator and payer enthusiasm for these products.”

Aug
06
2020

The investment gold rush continues for regenerative medicines

Pharmaceutical Commerce

The latest sector report from the Alliance for Regenerative Medicine (ARM), covering the first half of 2020, has a surprising finding: Despite the arrival of a global pandemic at the beginning of the year, new investment in cellular and genetic therapies (CGTs) and tissue engineering topped $10.7 billion globally—more than all of 2019. ARM expects the full-year data to exceed the previous record of $13.5 billion, set in 2018.

Aug
03
2020

Potential COVID-19 cell therapy treatments in development

BioWorld

Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases. In an Alliance for Regenerative Medicine (ARM) webinar on the topic, Michael Lehmicke, director, science and industry affairs at ARM, noted that developers are utilizing mesenchymal stem cells (MSCs) and other stromal cells to treat ARDS caused by COVID-19.

Jul
27
2020

Potential COVID-19 cell therapy treatments in development

BioWorld

Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases. In an Alliance for Regenerative Medicine (ARM) webinar on the topic, Michael Lehmicke, Director, Science and Industry Affairs at ARM, noted that developers are utilizing mesenchymal stem cells (MSCs) and other stromal cells to treat ARDS caused by COVID-19.

Jul
24
2020

Stakeholders Seek Increased User Fee Support for Biologics

PharmTech.com

At the public meeting to kick off negotiations for renewing the Prescription Drug User Fee Act (PDUFA) before the current program expires in September 2022, patient advocates, research experts, and industry similarly called for more user fee revenues to support CBER programs to advance these innovative therapies.